The reduction of survivin by treatment with YM155 and siSurvivin sensitized the cells to gemcitabine and osimertinib, indicating that inhibition of survivin expression is sufficient to chemosensitize A549 NSCLC cells to gemcitabine and osimertinib. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.